Pembrolizumab for the treatment of thoracic malignancies: Current landscape and future directions

Future Oncology

Volumn 12, Issue 1, 2016, Pages 9-23

  Karim, Safiya ^a   Leighl, Natasha ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

immune checkpoint inhibitors; immunotherapy; lambrolizumab; malignant pleural mesothelioma; MK 3475; non small cell lung cancer; PD 1 or PD L1 inhibitors; pembrolizumab; small cell lung cancer; targeted therapy

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; BIOLOGICAL MARKER; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROTEIN INHIBITOR; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ASTHENIA; CLINICAL TRIAL (TOPIC); DECREASED APPETITE; DRUG TARGETING; DYSPNEA; HUMAN; HYPOTHYROIDISM; IMMUNE SYSTEM; INFUSION RELATED REACTION; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SMALL CELL LUNG CANCER; SOLID TUMOR; THORAX CANCER; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; THORACIC NEOPLASMS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; THORACIC NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84951938171     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.294     Document Type: Review

References (61)

1. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012, version 1.0. Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. International Agency for Research on Cancer. Lyon, France. http://globocan.iarc.fr
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015).
3. Travis WD, Brambilla E, Riely GJ. New pathological classification of lung cancer: relevance for clinical practice and clinical trials. J. Clin. Oncol. 31, 992-1001 (2013).
4. Leighl NB. Treatment paradigms for patients with metastatic non-small cell lung cancer: first-, second-, and third-line. Curr. Oncol. 19(Suppl. 1), S52-S58 (2012).
5. Jansen R, Slingerland R, Goey S, Franks C, Bolhuis R and Stoter G. Interlukin-2 and interferon-alpha in the treatment of patients with advanced non-small cell lung cancer. J. Immunother. 12, 70-73 (1992).
6. Schiller J, Morgan-Ihrig C and Levitt M. Concomintant administration of interlukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am. J. Clin. Oncol. 18, 47-51 (1995).
7. Giaccone G, Bazhenova LA, Neumuinitis J et al. A Phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur. J. Cancer 51(16), 2321-2329 (2015).
8. Butts C, Socinski MA, Mitchell PL et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, Phase 3 trial. Lancet Oncol. 15(1), 59-68 (2014).
9. Lawrence MS, Stojanov P, Polak P et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457), 214-218 (2013).
10. Rivzi NA, Hellman MD, Snyder A et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124-128 (2015).
11. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
12. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
13. US Food and Drug Administration Press Release. www.fda.gov
14. US Food and Drug Administration website. www.accessdata.fda.gov
15. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009)
16. Ghandhi L, Balmanoukian A, Hui R et al. MK-3475 (anti-PD-L1 monoclonal antibody) for non-small cell lung cancer: anti-tumor activity and association with tumor PD-L1 expression. Cancer Res. 74, Abstract CT105 (2014).
17. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small cell lung cancer - supplementary appendix. N. Engl. J. Med. 372(21), 2018-2028 (2015).
18. Garon E, Leighl NB, Rizvi NA et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 32(Suppl. 5), Abstract 8020 (2014).
19. Merck Keynote clinical trials website. http://keynoteclinicaltrials.com
20. Clinical trials database: NCT01840579. https://clinicaltrials.gov
21. Clinical trials database: NCT02039674. https://clinicaltrials.gov
22. Paitnak A, Socinski MA, Gubens MA et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. J. Clin. Oncol. 33(Suppl.), Abstract 8011 (2015).
23. Clinical trials databse: NCT02007070. https://clinicaltrials.gov
24. Weiss GJ, Barndt H, Blaydorn L, Sangal A, Khemka V. Phase Ib/II study of pembrolizumab plus chemotherapy in advanced cancer: results of lung cancer patients receiving ≥ 1 prior line of therapy. Presented at: 16th Annual World Conference on Lung Cancer. Denver, CO, USA, 6-9 September 2015.
25. Clinical trials.database: NCT02085070. https://clinicaltrials.gov
26. Goldberg SB, Gettinger SN, Mahajan A et al. A Phase II trial of pembrolizumab for untreated brain metastases from non-small cell lung cancer. Presented at: 16th Annual World Conference on Lung Cancer. Denver, CO, USA, 6-9 September 2015.
27. Ott PA, Fernandez MEE, Hiret S et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028. J. Clin. Oncol. 33(Suppl.), Abstract 7502 (2015).
28. American Association for Cancer Research Press Release. www.aacr.org
29. Clinical trials.database: NCT02399371. https://clinicaltrials.gov
30. Clinical trials.database: NCT01905657. https://clinicaltrials.gov
31. Clinical trials.database: NCT02142738. https://clinicaltrials.gov
32. Clinical trials.database: NCT02220894. https://clinicaltrials.gov
33. Source: Bristol Myers Squibb. Press release: http://news.bms.com
34. Gettinger SN, Horn L, Ghandhi L et al. Overall survival and long-term safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated non-small cell lung cancer. J. Clin. Oncol. 33(18), 2004-2012 (2015).
35. Gettinger SN, Shepherd FA, Antonia SA et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. J. Clin. Oncol. 32(Suppl. 5s), Abstract 8024 (2014).
36. Rizvi NA, Antonia SJ, Chow LQM et al. A Phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). J. Clin. Oncol. 31(Suppl.), Abstract 8072 (2013).
37. Rizvi NA, Chowm LQM, Borghaei H et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J. Clin. Oncol. 32(Suppl. 5), Abstract 8022 (2014).
38. Clinical trials.database: NCT02393625. https://clinicaltrials.gov
39. Rizvi NA, Mazieres J, Planchard D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a Phase 2, single-arm trial. Lancet Oncol. 16(3), 257-265 (2015).
40. Spiegel DR, Reckamp KL, Rizvi NA et al. A Phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33(Suppl.), Abstract 8009 (2015).
41. Paz Azres L, Horn L, Borghaei H et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33(Suppl.), Abstract LBA109 (2015).
42. Antonia SJ, Bendell JC, Taylor MR et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J. Clin. Oncol. 33(Suppl.), Abstract 7503 (2015).
43. Johnson DB, Rioth MJ and Horn L. Immunotherapy for NSCLC. Curr. Treat. Options Oncol. 15, 658-669 (2014).
44. Freeman-Keller M and Weber JS. Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Ther. Adv. Med. Oncol. 7, 12-21 (2015).
45. Brahmer JR, Tykodi SS, Chow LQM et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
46. Source: Roche. Press release: www.roche.com
47. Horn L, Spiegel DR, Gettinger SN et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (antiPDL1) in non-small cell lung cancer (NSCLC): update from a Phase Ia study. J. Clin. Oncol. 33(Suppl.), Abstract 8029 (2015)
48. Spira AI, Park K, Mazieres J et al. Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). J. Clin. Oncol. 33(Suppl.), Abstract 8010 (2015).
49. Clinical trials database: NTC02008227. https://clinicaltrials.gov
50. Fairman D, Narwal R, Liang M et al. Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody in patients with advanced solid tumors. J. Clin. Oncol. 32(Suppl.), Abstract 2602 (2014).
51. Rizvi NA, Brahmer JR, Ou SI et al. Safety and clinical activity of MEDI4736, an antiprogrammed cell death ligand 1 (PDL1) antibody, in patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33(Suppl.), Abstract 8032 (2015).
52. Clinical trials database: NCT02352948. https://clinicaltrials.gov
53. Gulley JL, Spiegel D, Kelly K et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a Phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. J. Clin. Oncol. 33(Suppl.), Abstract 8034 (2015).
54. Clinical trials database: NCT02395172. https://clinicaltrials.gov
55. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
56. Gettinger SN, Horn L, Gandhi L et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small cell lung cancer. J. Clin. Oncol. 33(18), 2004-2012 (2015).
57. Sortino G. PD-L1 expression as a predictive biomarker in patients with non-small cell lung cancer: a pooled analysis. Presented at: 16th Annual World Conference on Lung Cancer. Denver, CO, USA, 6-9 September 2015.
58. Carbognin L, Pilotto S, Milella M et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed-death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS ONE 10(6), e0130142 (2015).
59. Powderly JD, Koeppen H, Hodi FS et al. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. J. Clin. Oncol. 31(Suppl.), Abstract e22118 (2013).
60. Wang A, Wang HY, Liu Y et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur. J. Surg. Oncol. 41(4), 450-456 (2015).
61. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7538), 563-567 (2014).